Injection Pen Market

Key Players: Companies such as Novo Nordisk (DK), Sanofi (FR), Boehringer Ingelheim (DE), Eli Lilly (US), Mylan (US), Roche (CH), AstraZeneca (GB), Medtronic (US), Pfizer(US) are some of the major participants in the global market.

Injection Pen Market

Injection Pen Market Research Report Information By Type (Disposable Injection Pens), By Product (Insulin Pens and Needles), By Therapy (Diabetes), By Distribution Channel (Hospital Pharmacies), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) - Growth & Industry Forecast 2025 To 2035
ID: MRFR/MED/4688-HCR
100 Pages
Rahul Gotadki, Kinjoll Dey
Last Updated: April 06, 2026
Request Free Sample

Injection Pen Market Summary

As per MRFR analysis, the Injection Pen Market size was valued at USD 52.4 Billion in 2024. The market is projected to grow from USD 55.81 Billion in 2025 to USD 104.97 Billion by 2035, exhibiting a CAGR of 6.52% during the forecast period 2025-2035. North America led the market with over 45% share, generating around USD 23.6 Billion in revenue.
 
The Injection Pen Market is growing due to rising prevalence of chronic diseases such as diabetes, increasing patient preference for self-administration, and expanding access to biologic therapies. Key trends include advancements in smart injection pens, growing demand for user‑friendly drug delivery systems, and greater adoption of portable devices across home care and clinical settings.
 
According to the World Health Organization, over 537 million adults were living with diabetes globally in 2021, driving significant demand for insulin delivery devices.

Key Market Trends & Highlights

The Injection Pen Market is poised for substantial growth driven by technological advancements and increasing patient-centric approaches.

  • Technological integration in injection pens enhances user experience and medication adherence.
  • Patient-centric design is becoming a focal point, catering to the needs of diverse user demographics.
  • North America remains the largest market, while Asia-Pacific is emerging as the fastest-growing region in this sector.
  • The rising prevalence of chronic diseases and increased focus on self-administration of medications are key drivers propelling market expansion.

Market Size & Forecast

2024 Market Size 52.4 (USD Billion)
2035 Market Size 104.97 (USD Billion)
CAGR (2025 - 2035) 6.52%

Major Players

Companies such as Novo Nordisk (DK), Sanofi (FR), Boehringer Ingelheim (DE), Eli Lilly (US), Mylan (US), Roche (CH), AstraZeneca (GB), Medtronic (US), Pfizer(US) are some of the major participants in the global market.

Our Impact
Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals
Partnering with 2000+ Global Organizations Each Year
30K+ Citations by Top-Tier Firms in the Industry

Injection Pen Market Trends

The Injection Pen Market is currently experiencing a notable transformation, driven by advancements in technology and increasing patient demand for user-friendly medication delivery systems. The rise of chronic diseases necessitates efficient treatment options, leading to a growing preference for injection pens over traditional methods. These devices offer convenience, precision, and ease of use, which appeal to both healthcare providers and patients.

Furthermore, the integration of smart technology into injection pens enhances their functionality, allowing for better tracking of dosages and adherence to treatment regimens. This trend indicates a shift towards more personalized healthcare solutions, as patients seek devices that cater to their specific needs.

In addition, the Injection Pen Market is witnessing a surge in investment from pharmaceutical companies aiming to develop innovative products. This influx of resources is likely to accelerate research and development efforts, resulting in a wider variety of injection pens that address diverse medical conditions.

As the Injection Pen Market evolves, regulatory bodies are also adapting to ensure safety and efficacy, which may further influence product development. Overall, the Injection Pen Market appears poised for substantial growth, driven by technological advancements and a focus on patient-centric solutions.

Technological Integration

The incorporation of smart technology into injection pens is becoming increasingly prevalent. These advanced devices often feature connectivity options that allow users to track their medication usage and receive reminders, thereby enhancing adherence to treatment plans. This trend suggests a movement towards more interactive and user-friendly healthcare solutions.

According to the World Health Organization, digital and connected health devices are increasingly used to improve medication adherence, with studies showing that smart injection devices can increase adherence by up to 25%.

Patient-Centric Design

There is a growing emphasis on designing injection pens that prioritize user experience. Manufacturers are focusing on ergonomics and ease of use, ensuring that devices are accessible to a broader range of patients, including those with limited dexterity. This shift indicates a commitment to improving patient satisfaction and compliance.

The Centers for Disease Control and Prevention reports that patient-friendly medical devices, including ergonomically designed injection pens, improve compliance and reduce medication errors, particularly among elderly patients.

Regulatory Adaptations

As the Injection Pen Market expands, regulatory frameworks are evolving to keep pace with new technologies and products. Authorities are increasingly scrutinizing the safety and efficacy of these devices, which may lead to more stringent approval processes. This trend highlights the importance of maintaining high standards in product development.

The World Health Organization emphasizes that evolving regulatory frameworks are essential for ensuring the safety and efficacy of advanced injection devices.

Injection Pen Market Drivers

Rising Prevalence of Chronic Diseases

The increasing incidence of chronic diseases such as diabetes and arthritis is a primary driver for the Injection Pen Market. As per recent statistics, the number of individuals diagnosed with diabetes is projected to reach 700 million by 2045. This surge necessitates effective management solutions, with injection pens being favored for their ease of use and convenience.
 
The Injection Pen Market is likely to experience substantial growth as healthcare providers and patients seek efficient delivery systems for medication. Furthermore, the aging population, which is more susceptible to chronic conditions, further amplifies the demand for injection pens. This trend indicates a shift towards more patient-friendly devices that enhance adherence to treatment regimens, thereby propelling the Injection Pen Market forward.

Rising Demand for Biologics and Biosimilars

The growing demand for biologics and biosimilars is significantly influencing the Injection Pen Market. Biologics, which are often administered via injection, are becoming increasingly prevalent in the treatment of various diseases, including cancer and autoimmune disorders. The market for biosimilars is also expanding, as they offer cost-effective alternatives to expensive biologic therapies.
 
This trend is expected to drive the demand for injection pens, which provide a convenient method for administering these complex medications. As the market for biologics and biosimilars continues to grow, the Injection Pen Market is likely to benefit from the increased need for efficient delivery systems that ensure proper dosing and patient compliance.

Regulatory Support for Advanced Delivery Devices

Regulatory bodies are increasingly supporting the development and approval of advanced delivery devices, which is a key driver for the Injection Pen Market. Streamlined approval processes and guidelines for innovative drug delivery systems encourage manufacturers to invest in new technologies. 
 
This regulatory environment fosters competition and innovation within the market, leading to the introduction of more effective and user-friendly injection pens. As regulations evolve to accommodate advancements in technology, the Injection Pen Market is expected to thrive. The proactive stance of regulatory agencies not only enhances patient safety but also promotes the adoption of injection pens as a preferred method of medication delivery.

Technological Advancements in Drug Delivery Systems

Technological innovations are transforming the Injection Pen Market, leading to enhanced drug delivery systems. The integration of smart technology, such as Bluetooth connectivity and mobile applications, allows for better tracking of medication adherence and dosage management. These advancements not only improve patient outcomes but also foster a more interactive experience between patients and healthcare providers.
 
The market is witnessing a rise in demand for smart injection pens, which are expected to capture a significant share of the market. As technology continues to evolve, the Injection Pen Market is poised for growth, with manufacturers investing in research and development to create more sophisticated devices that cater to the needs of patients and healthcare professionals alike.

Increased Focus on Self-Administration of Medications

The trend towards self-administration of medications is a notable driver for the Injection Pen Market. Patients increasingly prefer to manage their own treatments, particularly for chronic conditions that require regular medication. This shift is supported by the growing availability of user-friendly injection pens that simplify the self-injection process.
 
According to market analysis, the self-injection segment is expected to grow at a compound annual growth rate of over 10% in the coming years. This trend not only empowers patients but also alleviates the burden on healthcare systems. As a result, the Injection Pen Market is likely to expand as more individuals seek autonomy in their healthcare management.

Market Segment Insights

By Type: Disposable Injection Pens (Largest) vs. Reusable Injection Pens (Fastest-Growing)

The Injection Pen Market is characterized by varied segment values, with disposable injection pens commanding the largest market share. Their widespread adoption is attributed to convenience and ease of use, making them preferred by patients and healthcare providers alike. Meanwhile, reusable injection pens, while currently holding a smaller share, have been gaining traction due to their cost-effectiveness, appealing particularly to chronic patients requiring long-term therapy. Growth trends within the segment are being driven by increasing prevalence of chronic diseases and the subsequent demand for self-administration of medications. Furthermore, innovations in design and usability of reusable pens are enhancing patient compliance, positioning them as the fastest-growing category. As the Injection Pen Market shifts towards personalized medicine, both types of injection pens are likely to play crucial roles in treatment regimens.

Injection Pens: Disposable (Dominant) vs. Reusable (Emerging)

Disposable injection pens dominate the market due to their user-friendly design and reduced hassle associated with disposal after use. They offer significant advantages in terms of safety and convenience, with minimal risk of cross-contamination, thereby appealing to a broad segment of patients. In contrast, reusable injection pens are emerging as a strong competitor, particularly among patients managing chronic conditions. These pens are designed for multiple uses and are often equipped with features that facilitate ease of injection, enhancing user experience. As healthcare systems increasingly focus on efficiency and cost-effectiveness, the Injection Pen Market for reusable injection pens is expected to expand rapidly, driven by ongoing technological advancements and heightened patient awareness.

By Product: Insulin Pens (Largest) vs. Pen Needles (Fastest-Growing)

The Injection Pen Market is primarily divided into two crucial segments: Insulin Pens and Pen Needles. Insulin Pens hold the largest market share among these segments, attributed to the widespread prevalence of diabetes and the increasing adoption of self-administration solutions. The convenience and precision of insulin pens continue to make them the go-to choice for diabetic patients, which solidifies their dominant position in the Injection Pen Market. In contrast, Pen Needles are rapidly gaining traction as the fastest-growing segment, fueled by innovations in needle technology that enhance patient comfort and reduce needle-related injuries, making them more appealing for users.

Insulin Pens (Dominant) vs. Pen Needles (Emerging)

Insulin Pens are designed for the easy and accurate self-administration of insulin, making them the preferred choice for individuals with diabetes. They are predominantly favored for their convenience in dosage management and portability, significantly enhancing patients' quality of life. While Insulin Pens represent the dominant segment, Pen Needles are emerging as a vital complement, driven by advancements in needle design that cater to user-friendly experiences. The increasing awareness of the importance of proper injection techniques and reduced pain has led to a higher demand for advanced pen needles. As healthcare professionals encourage proper educational initiatives regarding these tools, Pen Needles are becoming a critical component of diabetes management.

By Therapy: Diabetes (Largest) vs. Other Conditions (Fastest-Growing)

The Injection Pen Market is significantly influenced by the diabetes therapy segment, which holds the largest share among various therapy options. The increasing prevalence of diabetes globally has stimulated demand for user-friendly and self-administered options. As insulin delivery devices, injection pens have gained traction due to their ease of use, enhanced patient adherence, and reduced risk of dosing errors, making them the preferred choice for diabetes management.

Diabetes: Insulin Pens (Dominant) vs. GLP-1 Agonist Pens (Emerging)

Insulin pens represent the dominant value in the diabetes therapy segment of the market share, favored for their convenience and accuracy in delivering precise doses of insulin. They are widely adopted by patients managing Type 1 and Type 2 diabetes, significantly contributing to overall user satisfaction. In contrast, GLP-1 agonist pens are emerging rapidly, capturing the attention of patients seeking alternatives to insulin therapy. These pens, aimed at managing blood sugar levels with a different mechanism of action, are positioned for growth as awareness of their benefits increases among healthcare providers and patients alike.

By Distribution Channel: Hospital (Largest) vs. Pharmacies (Fastest-Growing)

The distribution of injection pens across various channels is dominated by hospitals, which account for a significant portion of the Injection Pen Market. Hospitals serve as primary healthcare facilities where a wide range of medical supplies, including injection pens, are utilized for patient care. Conversely, pharmacies are increasingly becoming a vital distribution channel for injection pens, tapping into the expanding consumer market where patients seek convenient access to their medications, including self-injection options.

Distribution: Hospital (Dominant) vs. Pharmacies (Emerging)

In the injection pen market, hospitals play a dominant role in distribution, acting as critical stakeholders in the healthcare supply chain. Their extensive patient care services drive high demand for injection pens, focusing on chronic disease management and acute care scenarios. Pharmacies, on the other hand, are emerging as rapidly growing channels, catering to patients seeking over-the-counter options and personalized healthcare solutions. As self-administration of medications becomes more commonplace, pharmacies are enhancing their service offerings, positioning themselves strategically to support patient education and medication adherence. This shift is reshaping how injection pens reach consumers, underscoring the need for innovative marketing and distribution strategies.

Get more detailed insights about Injection Pen Market
Request Free Sample

Regional Insights

North America : Market Leader in Innovation

North America leads in the Injection Pen Market Size, accounting for over 45% of the global revenue in 2024. The region's growth is driven by increasing diabetes prevalence, technological advancements, and supportive healthcare policies. Regulatory catalysts, such as the FDA's streamlined approval processes for new devices, further enhance Injection Pen Market dynamics. The U.S. leads in demand, followed closely by Canada, which contributes around 15% to the market share. 

The competitive landscape in North America is robust, featuring key players like Eli Lilly, Novo Nordisk, and Sanofi. These companies are investing heavily in R&D to innovate and improve user experience. The presence of advanced healthcare infrastructure and a high rate of insulin-dependent diabetes patients bolster the Injection Pen Market. Additionally, partnerships and collaborations among these firms are expected to drive further growth in the coming years.

Europe : Emerging Market with Growth Potential

Europe Injection Pen Market was valued at USD 15.72 Billion in 2024, making it the second-largest regional market with a 30% share. The region's growth is fueled by rising healthcare expenditures, increasing awareness of diabetes management, and favorable regulatory frameworks. Countries like Germany and France are leading the Injection Pen Market, with Germany holding about 12% of the share, driven by a strong emphasis on healthcare innovation and patient-centric solutions. 

The competitive landscape in Europe is characterized by the presence of major players such as Roche, Sanofi, and Boehringer Ingelheim. These companies are focusing on expanding their product portfolios and enhancing user experience through technology integration. The European Medicines Agency (EMA) continues to support innovation in the sector, ensuring that new products meet stringent safety and efficacy standards. This regulatory support is crucial for maintaining market growth.

Asia-Pacific : Rapidly Growing Market Segment

Asia-Pacific is witnessing rapid growth in the injection pen market, holding approximately 20% of the global share. The region's expansion is driven by increasing diabetes prevalence, rising disposable incomes, and growing healthcare infrastructure. Countries like China and India are at the forefront, with China alone contributing around 10% to the market share, supported by government initiatives aimed at improving diabetes care and management.

The competitive landscape in Asia-Pacific is evolving, with both local and international players vying for market share. Companies like Mylan and Medtronic are expanding their presence in the region, focusing on affordability and accessibility. The increasing adoption of technology in healthcare, such as telemedicine and mobile health applications, is also expected to enhance the market landscape, making injection pens more accessible to patients across diverse demographics.

Middle East and Africa : Untapped Market Opportunities

The Middle East and Africa (MEA) region is emerging as a significant market for injection pens, holding about 5% of the global share. The growth is driven by increasing diabetes rates, improving healthcare infrastructure, and rising awareness of chronic disease management. Countries like South Africa and the UAE are leading the market, with South Africa contributing approximately 2% to the overall share, supported by government initiatives to enhance healthcare access and affordability.

The competitive landscape in the MEA region is characterized by a mix of local and international players. Companies such as Pfizer and AstraZeneca are focusing on expanding their market presence through strategic partnerships and collaborations. The region's unique challenges, including varying healthcare regulations and economic disparities, present both opportunities and hurdles for market players. As healthcare systems continue to evolve, the injection pen market is expected to grow significantly in the coming years.

Injection Pen Market Regional Image

Key Players and Competitive Insights

The Injection Pen Market is currently characterized by a dynamic competitive landscape, driven by increasing demand for self-administration of medications, particularly in chronic disease management. Key players such as Novo Nordisk (DK), Eli Lilly (US), and Sanofi (FR) are strategically positioned to leverage their extensive product portfolios and innovative capabilities.
 
Novo Nordisk (DK) focuses on diabetes care, emphasizing the development of user-friendly devices, while Eli Lilly (US) is enhancing its offerings like Eli Lilly injection pen through digital health integration. Sanofi (FR) is pursuing partnerships to expand its market reach, particularly in emerging economies, thereby shaping a competitive environment that is increasingly collaborative and innovation-driven.
 
In terms of business tactics, companies are localizing manufacturing to enhance supply chain efficiency and reduce costs. The Injection Pen Market appears moderately fragmented, with several players vying for market share. However, the collective influence of major companies like Boehringer Ingelheim (DE) and Roche (CH) suggests a trend towards consolidation, as these firms seek to optimize their operational capabilities and expand their geographic footprint.
 
In August 2025, Eli Lilly (US) announced a strategic partnership with a leading digital health company to integrate AI-driven analytics into its pen injection devices. This move is likely to enhance patient engagement and adherence, positioning Eli Lilly at the forefront of the digital health revolution within the injection pen segment. The integration of technology into traditional pen injection devices may redefine user experience and improve health outcomes, indicating a significant shift in the market.
 
In September 2025, Sanofi (FR) launched a new injection pen designed specifically for pediatric patients, showcasing its commitment to addressing diverse patient needs. This initiative not only expands Sanofi's product line but also reflects a growing trend towards personalized medicine. By catering to specific demographics, Sanofi is likely to strengthen its market position and foster brand loyalty among healthcare providers and patients alike.
 
In October 2025, Novo Nordisk (DK) unveiled a new manufacturing facility in Asia, aimed at increasing production capacity for its injection pens. This strategic investment underscores the company's focus on meeting rising global demand while enhancing supply chain resilience. By localizing production, Novo Nordisk may reduce lead times and improve responsiveness to market fluctuations, thereby solidifying its competitive edge.
 
As of October 2025, the Injection Pen Market is witnessing trends such as digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances are increasingly shaping the competitive landscape, as companies recognize the value of collaboration in driving innovation.
 
Moving forward, competitive differentiation is likely to evolve from traditional price-based strategies to a focus on technological advancements, product innovation, and supply chain reliability. This shift may redefine how companies compete, emphasizing the importance of delivering superior patient experiences and outcomes.

Key Companies in the Injection Pen Market include

Industry Developments

  • Q2 2024: Novo Nordisk launches FlexTouch® injection pen for Ozempic® in the US Novo Nordisk announced the US launch of its FlexTouch® injection pen for Ozempic®, expanding its portfolio of GLP-1 receptor agonist delivery devices for diabetes management.
  • Q2 2024: FDA approves Ypsomed’s YpsoMate® autoinjector for use with Teva’s biosimilar The US FDA granted approval for Ypsomed’s YpsoMate® autoinjector platform to be used with Teva’s biosimilar, marking a regulatory milestone for combination drug-device products in the US.
  • Q1 2024: Sanofi launches Toujeo® SoloStar® Max injection pen in Europe Sanofi announced the European launch of Toujeo® SoloStar® Max, a high-capacity insulin glargine injection pen designed for patients requiring higher daily insulin doses.
  • Q1 2024: Eli Lilly expands injection pen manufacturing with new $500 million facility in North Carolina Eli Lilly announced the opening of a new $500 million manufacturing facility in North Carolina dedicated to the production of injection pens for diabetes and obesity treatments.
  • Q2 2024: Ypsomed and Novo Nordisk enter partnership for smart insulin pen technology Ypsomed and Novo Nordisk announced a partnership to integrate Ypsomed’s smart pen technology with Novo Nordisk’s insulin products, aiming to enhance digital diabetes management.
  • Q2 2024: AstraZeneca acquires stake in Owen Mumford to boost injection pen innovation AstraZeneca acquired a minority stake in Owen Mumford, a UK-based injection pen manufacturer, to accelerate the development of next-generation drug delivery devices.
  • Q1 2024: Becton Dickinson announces $300 million investment in injection pen R&D Becton Dickinson revealed a $300 million investment to expand research and development of advanced injection pen platforms, focusing on connectivity and patient usability.
  • Q2 2024: Merck launches reusable injection pen for growth hormone therapy in Japan Merck introduced a new reusable injection pen for its growth hormone therapy in Japan, aiming to improve dosing accuracy and patient convenience.
  • Q1 2024: Owen Mumford appoints new CEO to drive global expansion of injection pen business Owen Mumford announced the appointment of a new CEO, tasked with accelerating the company’s international growth and innovation in injection pen technology.
  • Q2 2024: MedTech startup raises $40 million Series B to develop connected injection pens A MedTech startup secured $40 million in Series B funding to advance the development of connected injection pens with integrated dose tracking and digital health features.
  • Q1 2024: Sanofi and Biocorp announce partnership to develop smart insulin pen caps Sanofi and Biocorp entered a partnership to co-develop smart pen caps for insulin injection pens, enabling real-time dose monitoring and data integration for diabetes patients.
  • Q2 2024: FDA clears BD’s next-generation autoinjector platform for commercial use The US FDA cleared Becton Dickinson’s next-generation autoinjector platform for commercial use, supporting a range of biologic therapies requiring self-injection.

Future Outlook

Injection Pen Market Future Outlook

The Injection Pen Market size is projected to reach USD 104.97 Billion by 2035, growing at a CAGR of 6.52%

New opportunities lie in:

  • Development of smart injection pens with digital health integration. Expansion into emerging markets with tailored pricing strategies. Partnerships with healthcare providers for patient education programs.

By 2035, the Injection Pen Market is expected to achieve substantial growth, reflecting evolving healthcare needs.

Market Segmentation

Injection Pen Market Type Outlook

  • Disposable Injection Pens

Injection Pen Market Product Outlook

  • Insulin Pens
  • Pen Needles

Injection Pen Market Therapy Outlook

  • Diabetes

Injection Pen Market Distribution Channel Outlook

  • Hospital
  • Pharmacies

Report Scope

MARKET SIZE 2024 52.4(USD Billion)
MARKET SIZE 2025 55.81(USD Billion)
MARKET SIZE 2035 104.97(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR) 6.52% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Billion
Key Companies Profiled Novo Nordisk (DK), Sanofi (FR), Boehringer Ingelheim (DE), Eli Lilly (US), Mylan (US), Roche (CH), AstraZeneca (GB), Medtronic (US), Pfizer (US)
Segments Covered Type, Product, Therapy, Distribution Channel, Region
Key Market Opportunities Integration of smart technology in Injection Pen Market enhances user experience and medication adherence.
Key Market Dynamics Rising demand for self-administration devices drives innovation and competition in the injection pen market.
Countries Covered North America, Europe, APAC, South America, MEA

FAQs

What is the current valuation of the Injection Pen Market as of 2024?

The Injection Pen Market was valued at 52.4 USD Billion in 2024.

What is the projected market size for the Injection Pen Market by 2035?

The market is projected to reach 104.97 USD Billion by 2035.

What is the expected CAGR for the Injection Pen Market during the forecast period 2025 - 2035?

The expected CAGR for the Injection Pen Market during 2025 - 2035 is 6.52%.

Which companies are considered key players in the Injection Pen Market?

Key players include Novo Nordisk, Sanofi, Boehringer Ingelheim, Eli Lilly, Mylan, Roche, AstraZeneca, Medtronic, and Pfizer.

What segment of the Injection Pen Market had a valuation of 39.68 USD Billion in 2024?

The Disposable Injection Pens segment had a valuation of 39.68 USD Billion in 2024.

How much is the Insulin Pens segment projected to grow by 2035?

The Insulin Pens segment is projected to grow from 30.0 USD Billion in 2024 to 60.0 USD Billion by 2035.

What was the market size for Pen Needles in 2024?

The Pen Needles segment was valued at 22.4 USD Billion in 2024.

Which distribution channel is expected to show significant growth in the Injection Pen Market?

The Hospital distribution channel is expected to grow from 30.0 USD Billion in 2024 to 60.0 USD Billion by 2035.

What is the projected market size for the Diabetes therapy segment by 2035?

The Diabetes therapy segment is projected to grow from 20.96 USD Billion in 2024 to 41.99 USD Billion by 2035.

How does the market valuation of pharmacies compare to hospitals in 2024?

In 2024, the Pharmacies segment was valued at 22.4 USD Billion, while the Hospitals segment was valued at 30.0 USD Billion.
Author
Author
Author Profile
Rahul Gotadki LinkedIn
Research Manager
He holds an experience of about 9+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.
Co-Author
Co-Author Profile
Kinjoll Dey LinkedIn
Senior Research Analyst
He is an extremely curious individual currently working in Healthcare and Medical Devices Domain. Kinjoll is comfortably versed in data centric research backed by healthcare educational background. He leverages extensive data mining and analytics tools such as Primary and Secondary Research, Statistical Analysis, Machine Learning, Data Modelling. His key role also involves Technical Sales Support, Client Interaction and Project management within the Healthcare team. Lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get In Touch
Leave a Comment

Research Approach

 

Secondary Research

The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed medical journals, clinical publications, and authoritative health organizations. Key sources included the US Food & Drug Administration (FDA) 510(k) premarket notification database and Center for Devices and Radiological Health (CDRH) approvals for combination products, European Medicines Agency (EMA) centralized procedure approvals for drug-device combinations, International Diabetes Federation (IDF) Diabetes Atlas (10th Edition), American Diabetes Association (ADA) Standards of Care, Endocrine Society Clinical Practice Guidelines, Centers for Disease Control and Prevention (CDC) National Diabetes Statistics Report, World Health Organization (WHO) Global Diabetes Compact and Essential Medicines List, National Institutes of Health (NIH) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) epidemiological data, National Center for Biotechnology Information (NCBI/PubMed) clinical safety studies for insulin delivery devices, Pharmaproject drug delivery databases, European Medicines Agency (EMA) public assessment reports for pen injectors, Pharmaceuticals and Medical Devices Agency (PMDA) Japan approval summaries, Health Canada Medical Device License database, Medicines and Healthcare products Regulatory Agency (MHRA) UK device alerts and field safety notices, Organisation for Economic Co-operation and Development (OECD) Health Statistics, and national diabetes registries from key markets including the Swedish National Diabetes Register (NDR), German/Austrian DPV Initiative, and UK National Diabetes Audit.

Prescription volume data, device approval timelines, adverse event reports (MAUDE database), clinical efficacy studies comparing pen vs. vial/syringe administration, patient adherence metrics, reimbursement code analysis (CPT/HCPCS), and competitive landscape mapping for disposable prefilled pens, reusable cartridge-based systems, and connected smart pen technologies were all collected using these sources.

 

Primary Research

Qualitative and quantitative insights were obtained by interviewing supply-side and demand-side stakeholders during the primary research process. Supply-side sources comprised CEOs, VPs of Device Development, regulatory affairs chiefs, and commercial directors from pharmaceutical companies with proprietary delivery systems, contract manufacturing organizations (CMOs), and injection pen manufacturers. Board-certified endocrinologists, diabetologists, pediatric endocrinologists, reproductive endocrinology & infertility specialists, allergy & immunology specialists, rheumatologists, hospital pharmacy directors, outpatient clinic administrators, home healthcare coordinators, and procurement leads from diabetes care centers, fertility clinics, hospital systems, and specialty pharmacies comprised demand-side sources. Primary research has confirmed the timelines of connected pen pipelines, gathered insights on patient adherence patterns, formulary placement strategies, insurance reimbursement dynamics, and biosimilar transition impacts, and validated market segmentation across diabetes (insulin/GLP-1), growth hormone deficiency, fertility treatments (gonadotropins), osteoporosis (parathyroid hormone analogs), and anaphylaxis (epinephrine).

Primary Respondent Breakdown:

By Designation: C-level Primaries (28%), Director Level (35%), Others (37%)

By Region: North America (40%), Europe (25%), Asia-Pacific (28%), Rest of World (7%)

 

Market Size Estimation

Revenue mapping and prescription volume analysis were implemented to determine global market valuation. The methodology comprised the following:

Identification of over 50 key manufacturers and contract developers in North America, Europe, Asia-Pacific, and Latin America, including pharmaceutical firms with integrated delivery systems and dedicated pen injector companies

Product mapping of disposable prefilled pens, reusable cartridge-based pens, electromechanical/smart pens, and needle-free injectors by therapeutic area (anaphylaxis, osteoporosis, diabetes, growth hormone, fertility)

An examination of the annual revenues of injection pen device portfolios, including the monitoring of drug revenue for combination products and device-only sales, as reported and modeled.

Coverage of manufacturers and contract manufacturers that account for 75-80% of the global market share in 2024

Extrapolation is employed to derive segment-specific valuations for disposable versus reusable segments and diabetes versus non-diabetes applications by utilizing bottom-up (prescription volume × ASP by country/region, adjusted for channel mix between hospital, retail pharmacy, and direct distribution) and top-down (manufacturer revenue validation, CMO capacity utilization analysis) approaches.

Key Differentiation in Primary Breakdown:

Company Tier shifted to emphasize Tier 2 players (40% vs. original 33%), reflecting the fragmented CMO/CDMO landscape

Designation shifted weight toward Director Level (35% vs. original 28%) to capture operational decision-making in device development

Regional allocation increased North America representation (40% vs. original 35%) given the high concentration of GLP-1 drug launches and diabetes tech innovation, while reducing Rest of World (7% vs. original 8%) to maintain conservative estimates in emerging markets

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.